W
Wuhan Xiaoyaoyao Pharmaceutical Technology Co.
Innovative packaging solutions for pharmaceuticals, enhancing product safety and shelf life
About Wuhan Xiaoyaoyao Pharmaceutical Technology Co.
YBM100 specializes in providing advanced packaging solutions for the pharmaceutical industry. The company focuses on creating packaging that ensures the safety, efficacy, and extended shelf life of pharmaceutical products. YBM100 serves pharmaceutical manufacturers and healthcare providers by offering a range of packaging options tailored to meet stringent industry standards. Operating in the global pharmaceutical packaging market, YBM100 employs a business model that includes both direct sales and long-term contracts with major pharmaceutical companies. Revenue is generated through the sale of packaging materials and related services, including design and customization.
Source: Dealroom company dataKnowledge graph
News
Open roles
Wuhan Xiaoyaoyao Pharmaceutical Technology Co. in its local ecosystem
The Wuhan Xiaoyaoyao Pharmaceutical Technology Co. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Ameba Capital
Series A1 investor entered at this stage
Series B and later2 investors entered at this stage
Sequoia- LGLited Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wuhan Xiaoyaoyao Pharmaceutical Technology Co. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wuhan Xiaoyaoyao Pharmaceutical Technology Co. on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

